Jiangsu Hengrui Pharmaceuticals Hits Day High with Strong 3.34% Surge

Jiangsu Hengrui Pharmaceuticals Co., Ltd. has experienced a notable increase of 3.34% on July 1, 2026, reaching an intraday high of CNY 54.08. This performance stands out against the backdrop of the China Shanghai Composite, which only gained 0.44% on the same day. Over the past week, Jiangsu Hengrui has shown a robust performance with a 7.02% increase, significantly outperforming the broader market index, which saw a mere 0.04% rise. In terms of longer-term performance, Jiangsu Hengrui has recorded a 9.38% increase over the past month, while its year-to-date performance remains at -9.72%. The company’s market capitalization is substantial at CNY 292,524 million, categorizing it as a large-cap entity within the pharmaceuticals and biotechnology sector. Despite the recent uptick, the company has faced challenges in long-term growth, with net sales and operating profit growing at annual rates of 3.76% and 4.45%, respectively, over the last five years. The stock's price-to-earnings ratio stands at 37.00, reflecting a high valuation relative to its earnings.